SCHEMBL19196183

SCHEMBL19196183

C[C@]1(O)CC[C@H](NS(=O)(=O)c2ccc(-c3ncc(Cl)cc3F)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 2/20 0.44
MAP2K7 O14733 1/20 0.44
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SMO Q99835 1/20 0.42
PSEN1 P49768 2/20 0.39
PSEN2 P49810 2/20 0.39
APH1B Q8WW43 2/20 0.39
NCSTN Q92542 2/20 0.39
APH1A Q96BI3 2/20 0.39
PSENEN Q9NZ42 2/20 0.39
MAPT P10636 5/20 0.39
LMNA P02545 4/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
HTT P42858 2/20 0.39
KCNH2 Q12809 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TP53 P04637 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16335157 0.90 MAP2K4 (0.41) MAP2K4MAP2K7SMOLMNAALDH1A1
SCHEMBL16378418 0.90 MAP2K4 (0.46) MAP2K4MAP2K7KMT2ATDP1MAPT
SCHEMBL16378424 0.90 MAP2K4 (0.41) MAP2K4MAP2K7SMOLMNAALDH1A1
SCHEMBL16378447 0.90 MAP2K4 (0.41) MAP2K4MAP2K7SMOLMNAALDH1A1
SCHEMBL16335531 0.90 MAP2K4 (0.46) MAP2K4MAP2K7KMT2ATDP1MAPT
SCHEMBL19156761 0.90 MAP2K4 (0.46) MAP2K4MAP2K7KMT2ATDP1MAPT
SCHEMBL16335530 0.90 MAP2K4 (0.46) MAP2K4MAP2K7KMT2ATDP1MAPT
SCHEMBL17853849 0.85 MAP2K4 (0.38) MAP2K4MAP2K7ALDH1A1KCNH2CNR1
SCHEMBL17853456 0.85 MAP2K4 (0.38) MAP2K4MAP2K7ALDH1A1KCNH2CNR1
SCHEMBL17853463 0.85 MAP2K4 (0.38) MAP2K4MAP2K7ALDH1A1KCNH2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170217881-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2017-08-03 US disclosed
US-20170217881-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2017-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217881-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE BRCA1, TPMT, SOST MAP2K4 1966/4885MAP2K7 2772/4885KMT2A 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.